Loading…
Portmeds.com was cited for introducing unapproved and misbranded opioids, benzodiazepines, and Schedule II stimulants into interstate commerce via the internet in violation of the Federal Food, Drug, and Cosmetic Act (sections 301(a), 301(d), 301(k), 503(b), and 505(a)). The FDA emphasized particular concern regarding the public health risks associated with easy internet availability of these controlled substances, noting the severity of the opioid epidemic, the abuse potential of benzodiazepines—especially when combined with other drugs—and the high diversion risk of Schedule II stimulants. The agency specifically highlighted that polysubstance overdose deaths involving benzodiazepines account for the vast majority of overdose deaths in that drug category.